IMAGEENS
15.4.2021 11:43:05 CEST | Business Wire | Press release
IMAGEENS, a Paris-based medical Artificial Intelligence (AI) startup developing software solutions for the analysis of medical images, has secured 1.2Mn€ in seed financing. The round was led by Anaxago, with a participation from BADGE (Business Angels des Grandes Ecoles), COALESCENCE, and existing IMAGEENS investors.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210415005466/en/
IMAGEENS' software solutions allow radiologists, cardiologists and vascular surgeons to make personalized decisions and to better assess the cardiovascular risk of their patients, thanks to highly accurate medical imaging data.
The funding will allow IMAGEENS to accelerate the development and commercialization of ArtFun+, an artificial intelligence software and its prognostic biomarkers for cardiovascular imaging, and LABEL, an algorithmic solution for the automatic classification and valorization of medical imaging data. It will also allow to strengthen its team with key R&D talents and build its commercial team to scale the deployment of its software solutions.
"We are delighted to have been able to quickly complete this round table in collaboration with ANAXAGO. We will be able to announce the launch of several strategic projects as well as key hires in the coming months, which will be the cornerstones of IMAGEENS' development over the next few years," said Robert Baldwin, CEO of IMAGEENS .
ArtFun+ stems from the US National Institute of Health (NIH)-funded Multi-Ethnic Study of Atherosclerosis (MESA) which studied the prognostic power of imaging biomarkers on a multi-ethnic cohort of 3675 patients across the United States. In the study, the imaging biomarkers of ArtFun+ were shown to be highly predictive of death and hard cardiovascular for patients between 45 and 84 years old. Beyond the MESA trial, the imaging biomarkers of ArtFun+ were studied in 77 scientific publications and used in 31 leading clinical centers around the globe.
Today, IMAGEENS is in the process of obtaining FDA and CE-clearance for ArtFun+ in routine cardiovascular care to complement to cardiac MRI exams with cardiovascular risk biomarkers enabling improved follow-up and surgical decisions in ischemic cardiopathies, acute coronary syndrome, and aortic aneurysms.
Since late 2020, IMAGEENS has also developed a complementary business to its diagnostic solutions, by helping Europe’s largest medical data warehouses improve the quality of their medical data and use it for R&D and AI-training purposes. By working with leading medical institutions such as the AP-HP in Paris, IMAGEENS has developed a comprehensive set of image classification algorithms that automatically create metadata allowing the data warehouses to get a detailed understanding of the databases’ content, and the ability to precisely query the medical data to setup cohorts for R&D and AI-training projects.
ABOUT IMAGEENS
Founded in 2017, IMAGEENS develops software solutions for doctors to leverage the full potential of advanced medical imaging data. IMAGEENS commercializes two products: ArtFun+, an innovative software to calculate vascular stiffness and flow imaging biomarkers that are predictive of patients’ long-term risk of death and hard cardiovascular events, and LABEL, a set of image classification algorithms that enable large medical data warehouses to precisely query and create data cohorts for R&D and AI-training projects.
ABOUT ANAXAGO
Created in 2012, the Anaxago group is the first 100% digital private neo-bank, accessible to the greatest number of people, combining impact and performance. With more than 100,000 members, 250 companies and real estate projects financed since its creation and more than 250 million euros collected, Anaxago stands out for the selectivity and the support of the investment projects proposed on its platform. Anaxago is an independent group, majority owned by its founders, and currently has 40 employees. The investment in IMAGEENS was led by Alex Heraud and Gaston Vasseur. Anaxago counsels: M Guilain Hippolyte, Reed Smith LLP.
www.anaxago.com
ABOUT BADGE
Created in 2004 Les Business Angels des Grandes Ecoles is one of the largest networks of Business Angels in France. The mission is to support the development of emerging innovative projects with high growth potential. Since 2005 BADGE has financed 188 projects with 38 M€, having generated a total financing of more than 100 M€.
www.business-angels.info
ABOUT COALESCENCE
Coalescence is a network of Business Angels sharing the same values; they wish to promote the growth of young innovative projects. Beyond finance the members of Coalescence bring kind support with their various professional background.
www.coalescence.fr
View source version on businesswire.com: https://www.businesswire.com/news/home/20210415005466/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom